Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

July 2016

Orta ve ciddi Romatoid Artritte oral Janus Kinaz inhibitörü peficitinib'in (ASP015K) monoterapi olarak ekinlik ve güvenliği, Japonya verisi: 12 haftalık, randomize, çift-kör, plasebo-kontrollü faz llb çalışma

Ann Rheum Dis. 2016 Jun;75:1057-64. doi: 10.1136/annrheumdis-2015-208279. Epub 2015 Dec 15

Takeuchi et al.

Peficitinib (ASP015K) is a novel orally bioavailable JAK inhibitor in development for the treatment of RA. It inhibits JAK1, JAK2, JAK3 and Tyk2 enzyme activities and has moderate selectivity or JAK3 inhibition.Here the authors report the findings of a 12-week, randomized, double-blind, placebo-controlled phase IIb study evaluating efficacy, safety and dose response of peficitinib (25, 50, 100, or 150 mg) as once-daily oral monotherapy in Japanese patients with moderate to severe RA. The primar...

Keywords:

January 2016

Romatoid Artrit Klinik Çalışmalarında Tofasitinib ve Biyolojik DMARD Tedavisi ile Gözlenen Ciddi Infeksiyonların Sistematik Derleme ve Metaanalizi

Arthritis Res Ther. 2015 Dec 15;17(1):362

Geier J,

Menon S,

Riese R,

Boy M,

Gomez-Reino JJ

Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. By modulating the signalling of cytokines that are integral to lymphocyte activation, proliferation, and function, tofacitinib may suppress multiple elements of immune response. A systematic literature search including all biologics and tofacitinib procured 66 RCTs and 22 LTEs that were included in a meta-analysis to provide estimated incidence rates, risk ratios, and risk differences of serious infection for each therapy. Es...